Mounjaro is not a treatment for eating disorders. If you have been diagnosed with an eating disorder, discuss taking this medication with your medical providers. If you believe you have an eating disorder, please reach out to a qualified professional.

That said, GLP-1 receptor agonists have been shown to diminish binge eating.

“A plausible mechanism by which GLP-1 RA may induce weight loss is by suppressing appetite signalling in the brain and increasing satiety, leading to a reduced food intake [9, 10]. GLP-1 receptors are present in the central nervous system suggesting direct actions of GLP-1 in the brain [11]. GLP-1 infusions can enhance satiety and reduce energy intake in type 2 diabetes patients [12]. Furthermore, GLP-1 RA attenuates binge eating in obese patients [13], suggesting a role of GLP-1 RA in certain eating types.” From: The change of Testosterone after weight intervention in obese men September 2022 https://d197for5662m48.cloudfront.net/documents/publicationstatus/90792/preprint_pdf/bbf6c3fa17311652825b3fa8a057ea5e.pdf

“Glucagon-like peptide-1 (GLP-1) is a hormone secreted from the small intestine in response to food ingestion. It can regulate food intake by slowing gastric emptying and through appetite inhibition in the brain thus reducing activation in appetite-related brain regions (possible brain areas involved: vagus nerve, nodose ganglia, hypothalamic nuclei, and the brain stem). Liraglutide, a GLP-1 receptor agonist, has been recently also approved for obesity management as an adjunct to physical activity and diet recommendations. It was previously approved in the type-2 diabetes treatment due to its effects associated with releasing insulin from the pancreas and decreasing glucagon release.” Binge Eating Disorder: A 5-Year Retrospective Study on Experimental Drugs Journal of Experimental Pharmacology, January 2021 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7853418/

“Subjective ratings of appetite sensations were measured by a 100-mm visual analogue scale for parameters of hunger, fullness, satiety, and prospective food consumption pre- and 4-5h post-meal. Meal intake decreased on Day 2 (TZP 5 mg) and dose-dependently decreased with TZP vs. PBO on Day 51 (Figure). The proportion of meal occasions with ≥50% meal leftover was 0% (PBO) and 16.7% (TZP 5 mg) on Day 2 and 0% (PBO), 13.6% (TZP 5 mg), 18.2% (TZP 10 mg) and 30.0% (TZP 15 mg) on Day 51. There was a trend in decreasing hunger and fullness scores with all TZP doses vs. PBO on Day 51. However, satiety, prospective food consumption and overall appetite scores did not differ among groups. TZP dose-dependently reduced meal intake and demonstrated a trend in decreased hunger.” Effects of Tirzepatide on Meal Intake and Appetite in Japanese Patients with Type 2 Diabetes

Diabetes, Clinical Therapeutics/New Technology — Incretin based therapies, June 2020 https://diabetesjournals.org/diabetes/article/69/Supplement_1/969-P/56669/969-P-Effects-of-Tirzepatide-on-Meal-Intake-and

Mounjaro and Cardioprotectiveness While Tirzepatide is new as a dual agonist, there are ample studies on GLP-1RAs so where those articles apply, I’ve put them below.

“GLP-1RAs may also have the potential to favourably impact cardiovascular disease, obesity or neurological disorders in people without diabetes in the future.” From: The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems https://pubmed.ncbi.nlm.nih.gov/24373150/

GLP-1 Receptor Agonists: Effects on Cardiovascular Risk Reduction Cardiovascular Therapeutics, July 2013 https://onlinelibrary.wiley.com/doi/10.1111/1755-5922.12000